- Corporate Officers - R
- Riggs Rory B
Insider Trading History of Riggs Rory B
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Riggs Rory B since 2014.
This trader's CIK number is 1016835.
At the time of last reporting, Riggs Rory B was the Officer of Intra-cellular Therapies, Inc.. (stock ticker symbol ITCI).
Also see all insider trading activities at Intra-cellular Therapies, Inc..
Note that in the past
RIGGS RORY B also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Fibrogen Inc (FGEN) by Riggs Rory B
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2018 | FGEN | 0 | $0 | 55,000 | $3,034,181 | 0 | $0 |
| 2017 | FGEN | 0 | $0 | 25,000 | $1,298,000 | 0 | $0 |
| 2016 | FGEN | 0 | $0 | 20,000 | $417,320 | 0 | $0 |
| 2015 | FGEN | 0 | $0 | 50,000 | $1,398,592 | 0 | $0 |
Yearly summary of insider trading at Intra-cellular Therapies, Inc. (ITCI) by Riggs Rory B
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2022 | ITCI | 0 | $0 | 226,670 | $13,592,582 | 0 | $0 |
| 2021 | ITCI | 0 | $0 | 0 | $0 | 13,767 | $0 |
| 2020 | ITCI | 0 | $0 | 0 | $0 | 14,005 | $0 |
| 2019 | ITCI | 0 | $0 | 4,462 | $337,193 | 55,756 | $708,400 |
| 2017 | ITCI | 1,001 | $14,494 | 0 | $0 | 0 | $0 |
| 2014 | ITCI | 28,571 | $499,992 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Cibus, Inc. (CBUS) by Riggs Rory B
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | CBUS | 518,107 | $5,502,492 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Royalty Pharma Plc (RPRX) by Riggs Rory B
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | RPRX | 0 | $0 | 470,000 | $13,223,052 | 0 | $0 |
| 2023 | RPRX | 0 | $0 | 1,889,950 | $62,516,175 | 0 | $0 |
| 2021 | RPRX | 0 | $0 | 527,262 | $21,169,668 | 0 | $0 |
| 2020 | RPRX | 15,000 | $420,000 | 463,200 | $19,454,400 | 0 | $0 |
| 2002 | RPRX | 0 | $0 | 734,089 | $29,955,244 | 0 | $0 |
Insider trading activities at 4 companies by Riggs Rory B:
1. Fibrogen Inc (FGEN)
2. Intra-cellular Therapies, Inc. (ITCI)
3. Cibus, Inc. (CBUS)
4. Royalty Pharma Plc (RPRX)
Table 1. Insider trading of Fibrogen Inc (FGEN) by Riggs Rory B
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2018-03-12 | FGEN | Sale | 19,693 | 54.98 | 1,082,721 |
| 2018-03-13 | FGEN | Sale | 12,402 | 54.39 | 674,507 |
| 2018-03-09 | FGEN | Sale | 22,905 | 55.75 | 1,276,953 |
| 2017-09-13 | FGEN | Sale | 25,000 | 51.92 | 1,298,000 |
| 2016-12-16 | FGEN | Sale | 20,000 | 20.87 | 417,320 |
| 2015-09-11 | FGEN | Sale | 24,429 | 28.40 | 693,856 |
| 2015-09-14 | FGEN | Sale | 25,571 | 27.56 | 704,736 |
Table 2. Insider trading of Intra-cellular Therapies, Inc. (ITCI) by Riggs Rory B
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-06-18 | ITCI | Option Ex | 14,189 | .00 | 0 |
| 2024-06-24 | ITCI | Sale | 4,462 | 75.57 | 337,193 |
| 2024-06-23 | ITCI | Option Ex | 1,567 | .00 | 0 |
| 2024-06-24 | ITCI | Option Ex | 20,000 | 16.86 | 337,200 |
| 2024-03-20 | ITCI | Option Ex | 20,000 | 18.56 | 371,200 |
| 2022-03-16 | ITCI | Sale | 64,534 | 59.12 | 3,815,572 |
| 2022-03-17 | ITCI | Sale | 141,499 | 60.20 | 8,518,381 |
| 2022-03-18 | ITCI | Sale | 20,637 | 60.99 | 1,258,629 |
| 2021-05-27 | ITCI | Option Ex | 13,767 | .00 | 0 |
| 2020-06-25 | ITCI | Option Ex | 14,005 | .00 | 0 |
| 2017-12-29 | ITCI | Buy | 1,001 | 14.48 | 14,494 |
| 2014-02-05 | ITCI | Buy | 28,571 | 17.50 | 499,992 |
Table 3. Insider trading of Cibus, Inc. (CBUS) by Riggs Rory B
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-12-12 | CBUS | Buy | 517,107 | 10.58 | 5,470,992 |
| 2023-06-01 | CBUS | Buy | 1,000 | 31.50 | 31,500 |
Table 4. Insider trading of Royalty Pharma Plc (RPRX) by Riggs Rory B
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-01-04 | RPRX | Sale | 35,702 | 27.55 | 983,518 |
| 2024-01-02 | RPRX | Sale | 235,200 | 28.52 | 6,707,198 |
| 2024-01-03 | RPRX | Sale | 199,098 | 27.79 | 5,532,336 |
| 2023-05-22 | RPRX | Sale | 1,750,000 | 32.82 | 57,435,000 |
| 2023-03-30 | RPRX | Sale | 130,024 | 36.26 | 4,714,410 |
| 2023-03-29 | RPRX | Sale | 9,926 | 36.95 | 366,765 |
| 2002-12-12 | RPRX | Sale | 40,010 | 41.98 | 1,679,699 |
| 2022-12-09 | RPRX | Sale | 19,990 | 42.07 | 840,939 |
| 2022-11-17 | RPRX | Sale | 120,000 | 42.33 | 5,079,960 |
| 2022-09-15 | RPRX | Sale | 52,025 | 42.21 | 2,195,975 |
| 2022-09-14 | RPRX | Sale | 47,975 | 42.41 | 2,034,427 |
| 2022-08-09 | RPRX | Sale | 45,000 | 43.73 | 1,967,805 |
| 2022-06-29 | RPRX | Sale | 30,000 | 42.17 | 1,265,250 |
| 2022-05-19 | RPRX | Sale | 26,304 | 40.09 | 1,054,658 |
| 2022-05-20 | RPRX | Sale | 123,696 | 39.28 | 4,858,655 |
| 2022-03-29 | RPRX | Sale | 60,000 | 38.59 | 2,315,340 |
| 2022-03-18 | RPRX | Sale | 129,222 | 39.51 | 5,105,690 |
| 2022-03-21 | RPRX | Sale | 39,867 | 39.05 | 1,556,846 |
| 2021-12-29 | RPRX | Sale | 75,000 | 40.01 | 3,000,375 |
| 2021-12-28 | RPRX | Sale | 109,448 | 40.21 | 4,400,466 |
| 2021-11-16 | RPRX | Sale | 12,565 | 42.01 | 527,805 |
| 2021-11-17 | RPRX | Sale | 201,824 | 42.35 | 8,547,851 |
| 2021-09-28 | RPRX | Sale | 40,000 | 36.75 | 1,470,080 |
| 2021-09-29 | RPRX | Sale | 88,425 | 36.45 | 3,223,091 |
| 2020-10-20 | RPRX | Sale | 463,200 | 42.00 | 19,454,400 |
| 2020-06-18 | RPRX | Buy | 15,000 | 28.00 | 420,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Riggs Rory B
(Officer of Intra-cellular Therapies, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.